Drug Type AAV based gene therapy |
Synonyms scAAV-∆h IDUA op, Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene |
Target |
Action stimulants |
Mechanism IDUA gene stimulants(Alpha-L-iduronidase gene stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mucopolysaccharidosis I | Preclinical | United States | 07 May 2024 | |
| Mucopolysaccharidosis I | Preclinical | United States | 07 May 2024 |





